Yeah he was talking about me. But in my defense, I think I have a really good track record when it comes to CUBT.
I pumped it back in 2020 and it went from .007 to 23 cents. That is great by any measure.
I bashed the hell out of it in 2023 or so and in the next 2 years it went back down to .004 because I had a 'feeling' it was in a dead zone because of interest rates, new OTC rule changes, and financing for OTC companies went totally dry. It was a no win situation.
I am now VERY positive on CUBT because one...we have a new Sec of Health in charge who loves companies like CUBT. Two...because interest rates are falling or are predicted to fall. Three....because financing for LEGIT OTC companies like CUBT is loosening up. And four....because I think CUBT has a drug port that if successful is now worth multi billions and they are much closer to getting that developed than they ever have been. The US and western world population is aging. Aging means eye issues. CUBT has a potential treatment for that. The dog and pet angle is icing on the cake.
So far from my .004 call it has gone to almost .01 pre RS. Not huge. But ok. I think with the small OS and float (which is why I loved the RS considering it is a bio tech)....if the right things happen? This is a $100 a share stock or more if bio tech/short/drug port mania hits it.
Market Data 
Markets 
